NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $4.66 0.00 (0.00%) As of 05/19/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About CureVac Stock (NASDAQ:CVAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CureVac alerts:Sign Up Key Stats Today's Range$4.66▼$4.6650-Day Range$4.66▼$4.6652-Week Range$3.13▼$5.72VolumeN/AAverage Volume992,546 shsMarket Capitalization$1.05 billionP/E Ratio6.47Dividend YieldN/APrice Target$6.83Consensus RatingReduce Company Overview CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches. Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs. Its RNActive® platform underpins several vaccine candidates, including those targeting seasonal influenza, rabies and other viral pathogens. In oncology, the company is advancing individualized neoantigen vaccines and combination immunotherapies designed to stimulate targeted anti-tumor immune responses. Over the years, CureVac has entered collaborations with pharmaceutical partners to co-develop next-generation mRNA products, most notably a strategic partnership announced in 2021 focused on seasonal influenza vaccines. CureVac maintains research facilities in Germany and actively engages with the global scientific community through alliances and academic collaborations. The company also operates a presence in the United States to support clinical development and regulatory interactions. Leadership is led by Franz-Werner Haas, who has served as Chief Executive Officer since 2018, guiding CureVac’s transition from pioneering research to commercialization readiness. Supported by an interdisciplinary team of biologists, chemists and clinicians, the company continues to expand its platform capabilities and explore new indications for mRNA therapeutics.AI Generated. May Contain Errors. Read More Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVAC Stock News HeadlinesCureVac sues Moderna for patent infringement over COVID-19 vaccinesApril 24, 2026 | reuters.comCureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation PlanJanuary 22, 2026 | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 21 at 1:00 AM | Brownstone Research (Ad)BioNTech Completes CureVac Takeover and Updates Articles of AssociationJanuary 6, 2026 | tipranks.comBioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.December 23, 2025 | insidermonkey.comBioNTech Completes CureVac Acquisition to Bolster mRNA LeadershipDecember 18, 2025 | tipranks.comCureVac NV (CVAC): A bull case theoryDecember 4, 2025 | msn.comBioNTech Achieves Minimum Condition in CureVac Exchange OfferDecember 3, 2025 | globenewswire.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.52 at the start of the year. Since then, CVAC shares have increased by 3.1% and is now trading at $4.66. How were CureVac's earnings last quarter? CureVac N.V. (NASDAQ:CVAC) announced its quarterly earnings data on Monday, November, 24th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.07. The company earned $63.53 million during the quarter, compared to analyst estimates of $21.40 million. CureVac had a negative trailing twelve-month return on equity of 23.03% and a net margin of 199.92%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,333,333 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings11/24/2025Today5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CVAC's financial health is in the Green zone, according to TradeSmith. CVAC has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year Founded2000Price Target and Rating Average Price Target for CureVac$6.83 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+46.6%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.72 Trailing P/E Ratio6.47 Forward P/E Ratio6.47 P/E GrowthN/ANet Income$175.50 million Net Margins199.92% Pretax Margin232.79% Return on Equity-23.03% Return on Assets-19.09% Debt Debt-to-Equity Ratio0.03 Current Ratio3.70 Quick Ratio3.69 Sales & Book Value Annual Sales$70.74 million Price / Sales14.78 Cash Flow$0.99 per share Price / Cash Flow4.73 Book Value$3.36 per share Price / Book1.39Miscellaneous Outstanding Shares224,338,000Free Float219,515,000Market Cap$1.05 billion OptionableOptionable Beta1.77 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CVAC) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
